Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of CCI-779 (Temsirolimus) in Patients With Locally Advanced or Metastatic Breast Cancer

NCT00376688 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00376688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00376688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of CCI-779 (Temsirolimus) in Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2006
Completion date
December 16, 2019
Enrollment
31 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent breast carcinoma, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7